News

National MS Society Now Sponsored by Key Bike MS Supporter

TheĀ National Multiple Sclerosis SocietyĀ will receive an annual sponsorship from Showers PassĀ to support itsĀ efforts to improveĀ the quality of life of patients suffering from multiple sclerosisĀ (MS) as well as to find a cure for the disease. Showers Pass manufacturesĀ biking clothes and material and supportsĀ the…

Stem Cells Used to Treat Secondary Progressive Patients in Clinical Trial

What may work better than existing drugs to treat severe multiple sclerosis? Stem cells. A phase 2 clinical study from an international group of research centers compared head-to-head autologous hematopoietic stem cell transplantation (AHSCT) and mitoxantrone in treating patients with secondary progressive or relapsing-remitting multiple sclerosis. The findings showed that…

Scientists Update Recommendations on MS Research

Several renowned scientistsĀ working on multiple sclerosis (MS) recently joined forces to discuss and highlight the progressĀ and knowledgeĀ gapsĀ related toĀ MS research, the prospectsĀ of finding a cure for the disease, and a strategy to reduceĀ the burden the disease places onĀ patients. AĀ series of articles wasĀ published by the researchersĀ inĀ the…

Creative Medical Seeks Patent for Stem Cell Therapy for MS

Phoenix, Arizona-basedĀ Creative Medical Health (CMH) has just announced it has submitted a patent application for its proprietary mesenchymal stem cell pipeline product, indicated for autoimmune diseases. The companyĀ is already preparing to launch the product into its first line of clinical tests, which will…

Novel Antibody Drug Candidate From Chinese Drug Developer Shows Promise For Treating MS

MicroConstants China, Inc., a company thatĀ provides preclinical, clinical, and consulting services to biotechnology and pharmaceutical companies, has just announced it has acquired international rights to the development of AA98 antibody pipeline products, indicated for the treatment of several types of cancer, multiple sclerosis,Ā and age related macular degeneration…

Phase I Clinical Studies To Begin Using Anatabine Citrate as Possible Therapy For MS

Drug development companyĀ Rock Creek Pharmaceuticals, Inc.Ā recently announced that a newĀ clinical trial application with theĀ United Kingdom’sĀ Medicines Healthcare Products Regulatory Agency (MHRA) has been approved. The company is set to proceed with a Phase I study of its flagship pipeline product, Anatabine Citrate,Ā a chemical that is found naturally…

Stem Cell Transplantation May Improve Disability in Patients with Multiple Sclerosis

A new research study indicates that in patients with relapsing-remitting multiple sclerosis (MS), treatment with nonmyeloablative hematopoietic stem cell transplantation leads toĀ improvement in neurological impairment and quality of life. The study, entitled ā€œAssociation of Nonmyeloablative Hematopoietic Stem Cell Transplantation With Neurological Disability in Patients With Relapsing-Remitting Multiple…

Amarantus Acquires DioGenix to Bolster New MS Diagnostic Division

Amarantus BioScience Holdings, Inc. has announced the acquisition ofĀ DioGenix, Inc., which will be merged asĀ a newĀ foundational asset intoĀ a growing neuro-diagnostic division at AmarantusĀ calledĀ Amarantus Diagnostics. Amarantus BioScience isĀ dedicated to developing novel neurological diagnostic tests and therapy options in the fields ofĀ neurology, psychiatry, ophthalmology and regenerative diseases, including multiple…

Researchers Study Device to Improve Balance for MS Patients

Multiple sclerosis (MS) patients often experience difficultyĀ with balance and fear falling, which may prevent themĀ from being social or participating in exercise and community activities, affecting their quality of life. However, a pioneering study conducted atĀ the University of Massachusetts Amherst is looking to understand the role of…

Plegridy for Relapsing MS Now Approved in Scotland

The Scottish Medicines Consortium has just approved Biogen Idec’sĀ Plegridy (peg interferonĀ beta-1a) for the treatment of relapsing multiple sclerosis (MS) in patients between 18 to 65 years old, making the Consortium the first United Kingdom-based regulatory body to endorse the disease-modifying drug on the…